New hope for chronic hives? drug tested in small trial

This study tested whether ritlecitinib, a drug already approved for another condition, could safely reduce hives and itching in people with chronic spontaneous urticaria (CSU). The trial planned to enroll adults aged 18–65 who have had hives for over six weeks. Participants would take the drug for 12 weeks and track their symptoms daily. However, the study was withdrawn before any participants enrolled, so no results are available.